Cell-based assays are key components in the drug development process. Cell-based assays have several advantages over in vitro biochemical assays. They offer consistent tissue-specific responses in a biologically relevant microenvironment as opposed to biochemical assays.
It is also not possible to prepare or purify every target for biochemical measurement, which is a major factor limiting the applications of biochemical assays. As a result, pharmaceutical & biotechnology companies as well as CROs are replacing biochemical assays with cell-based assays for their lead identification and optimization processes in drug discovery.
Additionally, the physiological relevance of cell-based assays, as well as their ability to provide efficient, cost-effective, and accelerated drug discovery solutions, has also fueled their greater adoption among end users.
饾悊饾悶饾惌 饾悓饾惃饾惈饾悶 饾悎饾惂饾惉饾悽饾悹饾悺饾惌饾惉, 饾悊饾惈饾悮饾悰 饾悘饾悆饾悈 @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269
The introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies in cell-based assays has increased their reliability. However, these technologies have also resulted in a significant increase in the cost of instruments.
Due to this, even though better and superior reagents are available in the market, customers are restricted to using only those reagents specified in the license agreement. This may act as a barrier to the growth of the cell-based assays market.
For instance, the Global Health Innovative Technology (GHIT) Fund is a public-private partnership in Japan that funds various R&D activities for drug discovery, which also includes the screening of compound libraries related to various infectious diseases. R&D spending for new drug development is a critical growth driver for the global cell-based assays market.
The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period. The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting the growth of the market.